胸腺肽联合抗生素治疗肝硬化合并自发性细菌性腹膜炎的疗效观察  

Clinical study of thymic peptide combined with antibiotics in treatment of liver cirrhosis with spontaneous bacterial peritonitis

作　　者：汪慧兰[1] 

机构地区：[1]武汉市黄陂区人民医院感染科,湖北武汉430300

出　　处：《西部医学》2012年第2期334-335,337,共3页Medical Journal of West China

摘　　要：目的探讨胸腺肽联合抗生素治疗肝硬化合并自发性细菌性腹膜炎的临床疗效。方法 72例肝硬化合并自发性细菌性腹膜炎患者随机分为两组,对照组(36例)为常规保肝、抗感染及对症支持治疗,治疗组(36例)在常规治疗的基础上加用胸腺肽α11.6mg,隔日1次,皮下注射;两组疗程均为1个月。治疗前后观察两组患者临床症状、体征、腹水常规及培养结果。结果治疗组治疗总有效率(80.6%)明显优于对照组治疗总有效率(52.8%)(P<0.05);治疗组死亡率(8.3%)明显低于对照组死亡率(19.4%)(P<0.05);治疗组临床症状、体征、腹水常规和培养结果恢复正常的时间明显较对照组缩短(P<0.05)。结论胸腺肽联合抗生素治疗肝硬化合并自发性细菌性腹膜炎,能明显调节患者的机体免疫功能,提高治疗率和生存率。Objectiv To investigate the clinical efficacy of thymic peptide combined with antibiotics in the treatment of liver cirrhosis with spontaneous bacterial peritonitis.Methods 72 patients of liver cirrhosis with spontaneous bacterial peritonitis were randomly divided into treatment group（n=36） and control group（n=36）.The patients in the control group were treated by conventional treatment,while those in the treatment group were treated by thymic peptide α1,1.6mg,injected subcutaneously once per two days on the basis of conventional treatment.The treatment duration lasted one month for both the groups.Clinical symptoms and signs of changes,ascites practices and culture results were observed before and after treatment.Results The total effective rate of treatment group（80.6%） was significantly different compared to the total effective rate of control group（52.8%）（P0.05）;The mortality rate of treatment group（8.3%） was significantly lower than that of control group（19.4%）（P0.05）;The time of clinical symptoms,signs,ascites practices,culture results return to normal in treatment group was significantly shorter than the control group（P0.05）.Conclusion Thymic peptide combined with antibiotics in the treatment of liver cirrhosis with spontaneous bacterial peritonitis could significantly regulate the immune function of patients,improve the rates of treatment and survival.

关 键 词：胸腺肽 抗生素 肝硬化 自发性细菌性腹膜炎 

分 类 号：R656.41[医药卫生—外科学]